Wheezing Clinical Trial
Official title:
Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial
Ten percent of infants are prescribed short-acting bronchodilators (i.e. salbutamol) for wheezing every year, yet evidence to support this treatment in children younger than two years old is scarce. The aim of this study is to evaluate the effectiveness and safety of salbutamol for treatment of wheezing in young children who present to their primary care physician. In this study, the investigators will compare the effect of a 7-day treatment with salbutamol to the effect of 7-day treatment with a placebo. The main effect will be measured by evaluating a parent-reported symptom score. Additionally, the investigators will look at the presence of wheeze after 5 days, time to recovery, adverse events, healthcare utilisation, medication prescriptions, cost-effectiveness, and parent satisfaction with treatment.
BACKGROUND: Worldwide, 30% of all infants and young children experience an episode of wheezing (Matricaldi et al. 2008; Mallol at al. 2010; Martinez et al. 1995). Currently, there is no evidence to underpin the management of these children. National Belgian and Dutch primary care professional guidelines propose 'a trial of treatment' with short acting bronchodilators (i.e. salbutamol) for wheezing children below the age of six years and to evaluate treatment effect after 1 to 2 weeks, but convincing evidence is lacking (Chavasse et al. 2002). The effect of salbutamol has been studied well in children with proven asthma and is considered the first-line treatment in all patients in international asthma guidelines. However, trial findings of children with asthma are not applicable to primary care infants and young children with acute wheeze for several reasons; the anatomy and physiology in younger children differs significantly from those in older children and many infants and young children with an acute episode of wheezing do not experience further wheezing episodes later in life. As a result, it is at present unclear whether salbutamol inhalation therapy confers any benefit in young children who wheeze. OBJECTIVE: To evaluate the (cost-)effectiveness of salbutamol inhalations (4x200μg for 7 days) versus placebo in children aged 6-24 months presenting to their primary care physician with wheezing. DESIGN: A primary care based, randomised, placebo-controlled, multicentre, parallel group trial in 40 general practices and community paediatric practices in Belgium and the Netherlands. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04669288 -
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
|
Phase 3 | |
| Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
| Enrolling by invitation |
NCT00775697 -
Montelukast in Children With Wheezing
|
Phase 4 | |
| Completed |
NCT00749528 -
Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing
|
N/A | |
| Recruiting |
NCT00494624 -
Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children
|
Phase 4 | |
| Recruiting |
NCT04128592 -
Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers
|
N/A | |
| Recruiting |
NCT06093152 -
Video Assisted Study of Salbutamol Response in Viral Wheezing
|
||
| Completed |
NCT01452945 -
Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing
|
N/A | |
| Withdrawn |
NCT00628303 -
A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
|
Phase 3 | |
| Completed |
NCT01028560 -
Allergy Immunotherapy for the Reduction of Asthma
|
Phase 1/Phase 2 | |
| Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
| Completed |
NCT00507676 -
Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing
|
N/A | |
| Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
| Recruiting |
NCT06106646 -
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
|
||
| Recruiting |
NCT05710081 -
Bacterial Lysate In Preventing Asthma
|
Phase 3 | |
| Completed |
NCT04011709 -
A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy
|
Early Phase 1 | |
| Active, not recruiting |
NCT03377192 -
Impedance Pneumography in Assessment of Asthma Control in Preschool Children
|
||
| Completed |
NCT01142505 -
Wheeze and Intermittent Treatment
|
Phase 3 | |
| Active, not recruiting |
NCT04942483 -
Using Specific Tests in Preschool Children With Wheeze to Help us Determine the Necessity of Inhaled Corticosteroid Therapy (Feasibility Study).
|
||
| Recruiting |
NCT05684848 -
Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing
|
N/A |